Evolving roles of oncology pharmacists in Singapore: A survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre†
- 1 March 2008
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 14 (1), 23-29
- https://doi.org/10.1177/1078155207084009
Abstract
Background. National Cancer Centre (NCC) is currently the largest ambulatory oncology treatment centre in Singapore that treats mainly solid tumors and lymphomas. Oncology pharmacists at NCC play an active role in the management of CINV. In order to improve the clinical services delivered by pharmacy, particularly in the utilization of antiemetics, pharmacy department conducted a survey that aimed to understand the prescribing patterns of antiemetics for CINV. Objectives. ves. The primary aim of this study was to describe medical oncologists' perceptions of factors that can influence prescribing of antiemetics for acute and delayed nausea and vomiting associated with chemotherapy. A secondary aim was to assess medical oncologists' perception of antiemetic counseling by oncology pharmacists. Methods. This was a single-centered, non-randomized survey conducted at NCC in Singapore. Twenty-seven oncologists in the Department of Medical Oncology (DMO) were invited to participate in this survey. Survey forms were distributed to the medical oncologists at weekly DMO and tumor board meetings in November 2006. Results. Twenty oncologists returned surveys during the study period. Most oncologists closely adhered to the institution guideline on antiemetics utilization; however, results showed a trend of overprescribing acute antiemetics for low emetogenic chemotherapy regimens. Oncologists have identified anxiety, age and gender as the top three patient risk factors taken into consideration when they prescribe antiemetics. Majority of oncologists found pharmacists' counseling on antiemetics to be effective. Conclusions. Through this survey, oncology pharmacists at NCC were able to identify areas of antiemetics utilization that needed refinement. Results from this survey provide opportunities for oncology pharmacists to collaborate with medical oncologists to further improve the management of chemotherapy induced nausea and vomiting. J Oncol Pharm Practice (2008) 14: 23—29.Keywords
This publication has 29 references indexed in Scilit:
- Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic TreatmentJournal of Clinical Oncology, 2006
- Evaluation of Clinical Pharmacy Services in a Hematology/Oncology Outpatient SettingAnnals of Pharmacotherapy, 2006
- American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006Journal of Clinical Oncology, 2006
- Incidence of chemotherapy‐induced nausea and emesis after modern antiemeticsCancer, 2004
- From oncology pharmacy to pharmaceutical care: new contributions to multidisciplinary cancer careSupportive Care in Cancer, 2004
- Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemeticsCancer, 2003
- Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patientsSupportive Care in Cancer, 2002
- Standard treatment of chemotherapy-induced emesisSupportive Care in Cancer, 1997
- Differences in nausea, vomiting, and retching between younger and older outpatients receiving cancer chemotherapyCancer Nursing, 1996
- Cancer therapy-induced emesis: the nurse's perspectiveEuropean Journal of Cancer Care, 1994